Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719157 | 0.78 | SLC6A4 (0.39) | SLC6A4SLC6A3SLC6A2SIGMAR1ALDH1A1 | |
| SCHEMBL4668444 | 0.77 | SLC6A4 (0.40) | SLC6A4SLC6A3SLC6A2SIGMAR1ALDH1A1 | |
| SCHEMBL4719154 | 0.74 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1CYP2D6KDM4EKMT2A | |
| SCHEMBL4868499 | 0.72 | ALDH1A1 (0.51) | SLC6A4SLC6A3SLC6A2SIGMAR1ALDH1A1 | |
| SCHEMBL9491754 | 0.70 | SLC6A3 (0.46) | SLC6A4SLC6A3SLC6A2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL10839428 | 0.70 | KCNH2 (0.60) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2543003 | 0.69 | PYCR1 (0.58) | SLC6A4SLC6A3SLC6A2SIGMAR1ALDH1A1 | |
| SCHEMBL8565602 | 0.69 | SLC6A3 (0.39) | SLC6A4SLC6A3SLC6A2ALDH1A1LMNA | |
| SCHEMBL16650034 | 0.68 | SLC6A3 (0.41) | SLC6A4SLC6A3SLC6A2ALDH1A1LMNA | |
| SCHEMBL4637181 | 0.68 | SIGMAR1 (0.67) | SIGMAR1ALDH1A1CYP3A4CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1931620-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007034252-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | SLC6A4 3538/4885SLC6A3 2734/4885SLC6A2 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.